Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ALLO-605 |
| Trade Name | |
| Synonyms | ALLO 605|ALLO605 |
| Drug Descriptions |
ALLO-605 are allogeneic T-cells engineered to express a BCMA targeting chimeric antigen receptor (CAR), with TRAC and CD52 gene inactivation, which may lead to antitumor activity (Blood (2020) 136 (Supplement 1): 8). |
| DrugClasses | TNFRSF17 Immune Cell Therapy 27 |
| CAS Registry Number | NA |
| NCIT ID | C182066 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ALLO-605 | ALLO-605 | 0 | 0 |
| ALLO-605 + ALLO-647 + Cyclophosphamide + Fludarabine | ALLO-605 ALLO-647 Cyclophosphamide Fludarabine | 0 | 1 |